# NanaBis™ an Oro-buccal Administered delta9-Tetrahydrocannabinol (d9-THC) & Cannabidiol (CBD) Medicine for the Management of Bone Pain From Metastatic Cancers

> **NCT04808531** · PHASE3 · UNKNOWN · sponsor: **Medlab Clinical** · enrollment: 360 (estimated)

## Conditions studied

- Cancer Related Pain

## Interventions

- **DRUG:** NanaBis™
- **DRUG:** Oxycodone CR
- **DRUG:** Placebo Spray
- **DRUG:** Placebo Tablet
- **DRUG:** Oxycodone IR

## Key facts

- **NCT ID:** NCT04808531
- **Lead sponsor:** Medlab Clinical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-11
- **Primary completion:** 2024-02
- **Final completion:** 2024-06
- **Target enrollment:** 360 (ESTIMATED)
- **Last updated:** 2022-04-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04808531

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04808531, "NanaBis™ an Oro-buccal Administered delta9-Tetrahydrocannabinol (d9-THC) & Cannabidiol (CBD) Medicine for the Management of Bone Pain From Metastatic Cancers". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04808531. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*